Pharmaceutical laws and regulations in Iran: An overview von Zaboli, Pardis, Hashemi-Meshkini, Amir, Varmaghani, Mehdi, Gholami, Hadi, Vazirian, Iman, Zekri, Hedieh-Sadat, Eslamitabar, Shahriar, Kebriaeezadeh, Abbas

Volltext

Developing a patient satisfaction questionnaire for services provided in Iranian community pharmacies von Yaghoubifard, Saeed, Rashidian, Arash, Kebriaeezadeh, Abbas, Sheidaei, Ali, Varmaghani, Mehdi, Hashemi-Meshkini, Amir, Zekri, Hedieh-Sadat

Volltext

Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis von Kebriaeezadeh, Abbas, Meshkini, AmirHashemi, Varahrami, Vida, Varmaghani, Mehdi, Yaghoubifard, Saeed, Yousefi, Mehdi, Zekri, Hedieh-Sadat, Anabi, Majid, Darzi, EhsanRezaei, Farzadfar, Farshad

Volltext

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies? von Kebriaeezadeh, Abbas, Nikfar, Shekoufeh, Varmaghani, Mehdi, Yaghoubifard, Saeed, Yousefi, Mehdi, Zekri, Hedieh-Sadat, Hashemi-Meshkini, Amir

Volltext

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis von Hashemi-Meshkini, Amir, Zekri, Hedieh Sadat, Karimi-Yazdi, Hasan, Zaboli, Pardis, Sahraian, Mohammad Ali, Nikfar, Shekoufeh

Volltext

An overview to pharmaceutical financing in Iran von Mehdi Varmaghani, Amir Hashemi-Meshkini, Akbar Abdollahiasl, Elham Heidari, Hedieh-Sadat Zekri, Saeed Yaghoubifard, Farid Dorkoosh

Volltext

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis von Hashemi-Meshkini, Amir, Zekri, Hedieh Sadat, Karimi-Yazdi, Hasan, Zaboli, Pardis, Sahraian, Mohammad Ali, Nikfar, Shekoufeh

Volltext